MetaADEDB 2.0 @ LMMD
GDC-0973
(BSMCAPRUBJMWDF-KRWDZBQOSA-N)
Structure
SMILES
Ic1ccc(c(c1)F)Nc1c(ccc(c1F)F)C(=O)N1CC(C1)(O)[C@@H]1CCCCN1
Type(s)
Approved; Investigational
ATC code(s)
L01XE38
Molecular Formula:
C21H21F3IN3O2
Molecular Weight:
531.310
Log P:
4.1208
Hydrogen Bond Acceptor:
4
Hydrogen Bond Donor:
3
TPSA:
64.6
CAS Number(s):
934660-93-2
Synonym(s)
1.
GDC-0973
2.
(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone
3.
XL518
4.
cobimetinib
External Link(s)
MeSHC574276
PubChem Compound16222096
BindingDB50391802
ChEBI90851
CHEMBLCHEMBL2146883
DrugBankDB05239
DrugCentral5046
IUPHAR/BPS Guide to PHARMACOLOGY7626
KEGGdr:D10405
Therapeutic Target DatabaseD0O2FN
ZINC60325170
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Intentional product use issueFAERS: 7US FAERS
2No adverse eventFAERS: 7US FAERS
3FatigueFAERS: 5US FAERS
4AcneFAERS: 3US FAERS
5AlopeciaFAERS: 3
Canada Vigilance: 1
Canada Vigilance
US FAERS
6Intercepted medication errorFAERS: 3US FAERS
7MyalgiaFAERS: 3US FAERS
8NauseaFAERS: 3US FAERS
9VomitingFAERS: 3US FAERS
10Blood creatine phosphokinase increasedFAERS: 2US FAERS
11Blood creatinine increasedFAERS: 2US FAERS
12Disease ProgressionFAERS: 2US FAERS
13DizzinessFAERS: 2US FAERS
14DyspepsiaFAERS: 2US FAERS
15HypersomniaFAERS: 2US FAERS
16Incorrect product storageFAERS: 2US FAERS
17PneumoniaFAERS: 2US FAERS
18Skin toxicityFAERS: 2US FAERS
19Toxic Epidermal NecrolysisFAERS: 2
Canada Vigilance: 2
Canada Vigilance
US FAERS
20Visual ImpairmentFAERS: 2US FAERS
21AbasiaFAERS: 1US FAERS
22Abdominal PainFAERS: 1US FAERS
23Abdominal discomfortFAERS: 1US FAERS
24Alanine Aminotransferase IncreasedFAERS: 1US FAERS
25AmnesiaFAERS: 1US FAERS
26AngerFAERS: 1US FAERS
27ArthralgiaFAERS: 1US FAERS
28Aspartate Aminotransferase IncreasedFAERS: 1US FAERS
29AstheniaFAERS: 1US FAERS
30BlindnessFAERS: 1US FAERS
31Capillary Leak SyndromeFAERS: 1US FAERS
32Cardiac function test abnormalFAERS: 1US FAERS
33Cerebral disorderFAERS: 1US FAERS
34Cerebrovascular accidentFAERS: 1US FAERS
35ChillsFAERS: 1US FAERS
36Dark circles under eyesFAERS: 1US FAERS
37DehydrationFAERS: 1US FAERS
38DermatitisFAERS: 1US FAERS
39DiscomfortFAERS: 1US FAERS
40Drug ineffectiveFAERS: 1US FAERS
41Dry skinFAERS: 1US FAERS
42DysgeusiaFAERS: 1US FAERS
43EpistaxisFAERS: 1US FAERS
44FlatulenceFAERS: 1US FAERS
45Gastric pH decreasedFAERS: 1US FAERS
46Gastrointestinal perforationFAERS: 1US FAERS
47Gastrointestinal toxicityFAERS: 1US FAERS
48Hypertrophic CardiomyopathyFAERS: 1US FAERS
49Incorrect route of drug administrationFAERS: 1US FAERS
50Intentional product misuseFAERS: 1US FAERS
51Lip swellingFAERS: 1US FAERS
52LymphadenopathyFAERS: 1US FAERS
53MalaiseFAERS: 1US FAERS
54Muscle tightnessFAERS: 1US FAERS
55Myocardial InfarctionFAERS: 1US FAERS
56Neurological decompensationFAERS: 1US FAERS
57NeutropeniaFAERS: 1US FAERS
58Oropharyngeal painFAERS: 1US FAERS
59Peripheral swellingFAERS: 1US FAERS
60Product storage errorFAERS: 1US FAERS
61PruritusFAERS: 1US FAERS
62PurulenceFAERS: 1US FAERS
63Respiratory FailureFAERS: 1US FAERS
64RhabdomyolysisFAERS: 1US FAERS
65SyncopeFAERS: 1US FAERS
66ThrombocytopeniaFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
67Tracheal fistulaFAERS: 1US FAERS
68TremorFAERS: 1US FAERS
69UrticariaFAERS: 1US FAERS
70UveitisFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.